icometrix

Exploring the future of #neuroradiology at #WNRS25 in Monterey, California 🇺🇸 from Oct 23–26? Join Dirk Smeets, CTO of icometrix, to see how icobrain supports objective, quantitative brain #MRI analysis across diverse neurological conditions. From lesion load in multiple sclerosis to structural changes in dementia, stroke, epilepsy, and traumatic brain injury, #icobrain delivers consistent, reproducible measurements that help clinicians track disease progression and treatment response with confidence. With FDA-cleared and CE-marked solutions, trusted by hospitals, research centers, and pharmaceutical partners worldwide, #icobrain integrates seamlessly into clinical workflows—enhancing decision-making while maintaining efficiency and reliability. 🤝 Meet Dirk Smeets at #WNRS2025 to explore how clinically validated #AI is transforming #neuroradiology into a more precise, data-driven practice.

Attending #LausanneXII in Switzerland 🇨🇭 from October 21–23? Meet Jaime Simarro Viana, PhD to learn how icobrain dm and icobrain aria provide objective, quantitative insights that support clinicians in Alzheimer’s disease care. With clinically validated #AI, icobrain dm quantifies brain atrophy, white matter hyperintensities, and other structural biomarkers from MRI—providing #neurologists and #neuroradiologists with consistent, longitudinal measurements to monitor cognitive decline and disease progression. icobrain aria supports the evaluation and monitoring of ARIA-E and ARIA-H findings in patients undergoing anti-amyloid therapy, offering standardized volumetric analysis that enhances diagnostic confidence and treatment decision-making. Trusted by leading hospitals, research centers, and pharmaceutical partners worldwide, icobrain integrates seamlessly into clinical and research workflows, providing FDA-cleared and CE-marked solutions for quantitative brain #MRI analysis. 🤝 Connect with Jaime Simarro Viana, PhD in Lausanne to discover how #icobrain supports precision #neuroimaging and advances #Alzheimer’s disease management.

Spotted in Times Square. Yesterday, icometrix was featured on the Nasdaq Tower in New York as part of the 2025 MedTech Innovator cohort. It was a proud moment for the team. Not because of the screen, but because of what it represents - years of building, listening, validating, and pushing to support clinicians in real-world care. The program gave us the chance to connect with some brilliant people and companies all working toward better healthcare. We're grateful to be among them. Thanks to MedTech Innovator for the opportunity - and to everyone who's been part of this with us.

AI is changing the way we detect, diagnose, and monitor Alzheimer’s disease. In our latest blog, we explore how icobrain dm and icobrain aria support earlier diagnoses, treatment eligibility assessments, and standardized ARIA monitoring - enabling radiologists and neurologists to deliver safer, data-driven care. With icobrain dm and icobrain aria, radiologists and neurologists gain objective, reproducible insights that support confident decision-making - from differentiating dementia subtypes to safely monitoring anti-amyloid therapy. ✅ icobrain dm helps differentiate markers of the different types of dementia by quantifying brain volume relative to healthy controls, and assesses eligibility for anti-amyloid treatment. ✅ icobrain aria enables standardized ARIA-E and ARIA-H assessments, supporting ongoing safety monitoring and treatment management. By integrating both solutions into your clinical workflow, you can deliver data-driven, consistent, and patient-centered #Alzheimer's care. 👇 Read more about how #AI can enhance your diagnostic and monitoring workflow in our new blog through the link in the comments!

Attending #SENRS2025 in New Orleans 🇺🇸 from October 16-19? Then meet Kathy Hampton and Matt Cominsky from icometrix to learn how icobrain brings precision, consistency, and confidence to clinical #neuroimaging. With clinically validated #AI, icobrain provides quantitative insights from brain MRI, supporting #neuroradiologists and #neurologists in assessing lesion load, atrophy, and other key biomarkers across neurological conditions—including Multiple Sclerosis, ARIA, dementia, stroke, epilepsy and TBI. Trusted by leading hospitals, research institutions, and pharmaceutical partners worldwide, icobrain integrates seamlessly into existing workflows, delivering secure, FDA-cleared and CE-marked solutions for objective brain #MRI analysis. 🤝 Connect with Kathy and Matt to discover why #icobrain is the trusted standard in precision #neuroimaging AI.

Part of the EU-funded CLAIMS project, #RECLAIM is a retrospective, multicenter observational study advancing personalised, data-driven management of #MultipleSclerosis (#MS). Key goals: • Develop and validate progression-related biomarkers • Build AI tools to predict individual disease trajectories • Gain insights into disease progression, prognosis, and treatment response Cohort progress: • 49,334 MRI datasets from 5,068 patients • Clinical data from 2,803 patients • OCT scans from 168 patients These numbers reflect the data analysed so far and are rapidly increasing as partners finalise data transfers and ongoing analyses. The RECLAIM cohort includes individuals with MS, CIS, RIS, NMOSD, and MOGAD, with all data securely processed and mapped into an MS-specific Common Data Model (CDM). For more information, please refer to our website: 👉 https://lnkd.in/dHCQvpkk The validation of the first generation of AI-based prognostic and treatment tools is currently underway,  bringing us one step closer to truly personalised care for people living with MS. 👏 A big thank you to all partners for making this milestone possible! Innovative Health Initiative (IHI)

With anti-amyloid therapies being rolled out progressively, hospitals worldwide are turning to icobrain to operationalize AD care workflows - safely, efficiently, and at scale. From early detection to treatment monitoring, icobrain provides the structure and clinical clarity needed in today’s Alzheimer’s care: ✅ icobrain dm delivers objective volumetric and asymmetry measurements that support early and differential diagnosis, helping identify eligible patients with greater confidence. ✅ icobrain aria supports safety monitoring by quantifying ARIA-E and ARIA-H, enabling timely and consistent decisions on therapy continuation or adjustment. Integrated into PACS and built around real-world clinical needs, icobrain is already the foundation of Alzheimer’s workflows at leading institutions worldwide. See how #icobrain can support your team - and share with colleagues who are preparing for this next era in Alzheimer’s care.  #Neuroimaging #Radiology #AntiAmyloid #neurology #radiology #neuroradiolgy

Are you attending JFR.plus in Paris today? Then connect with Jan Verheyden on-site to learn how our clinically validated solutions support more confident diagnoses, streamline workflows, and improve patient outcomes. Discover how #icobrain integrates seamlessly into clinical practice and is backed by peer-reviewed research and global adoption. See why icobrain is trusted globally.

Two weeks. Two conferences. One clear message: clinically validated AI is shaping the future of #neuroimaging. From #ESNR2025 in Istanbul 🇹🇷 to #ECTRIMS2025 in Barcelona 🇪🇸, #icobrain was at the center of conversations on how objective, quantitative imaging is transforming clinical care and research in #neurology. At #ESNR, our team – Ricardo Magalhaes, Jan Verheyden, and Vincenzo Anania – joined discussions on some of the most pressing topics in neuroradiology, including: ▪️ Differential diagnosis in dementia and the role of imaging biomarkers ▪️ #ARIA monitoring and treatment safety in Alzheimer’s disease ▪️ Precision imaging for #MS, #TBI, #stroke, and beyond At #ECTRIMS, Lars Costers, Wim Van Hecke, and Vincenzo Anania met with leaders in multiple sclerosis care to showcase how icobrain ms and icobrain ms+ deliver consistent, quantitative insights from brain #MRI—helping clinicians track lesion load, brain atrophy, and disease progression with confidence. Paired with icompanion, real-world data and patient-reported outcomes complete a holistic view of #MS management. Across both meetings, one theme was clear: 👉 Clinically validated, regulatory-cleared #AI is no longer a future ambition—it’s the trusted standard in precision #neuroimaging today. Many thanks to the organizers, speakers, and collaborators for the engaging discussions and continued partnership.

When it comes to AI in medical imaging, few explain the stakes more clearly than Dr. Dr Hugh Harvey—radiologist-turned-regulatory expert and Managing Director at Hardian Health. In this video, he breaks down CADt, CADe, and CADe/x—and explains why CADe/x systems offer the most clinical value, but face the greatest regulatory hurdles (often taking up to two years for clearance). Most AI tools today are CADt or CADe - faster to clear, but limited in scope. Few reach CADe/x: delivering diagnostic outputs that radiologists can directly integrate into their decision-making. Reaching CADe/x requires more than strong detection algorithms. It demands: ▪️ Evidence & validation: It’s not enough to show detection accuracy. You must generate robust clinical trials, peer-reviewed publications, and real-world performance data to validate diagnostic claims. ▪️ Regulatory approval: Claims must be explicitly tied to intended use, and the evidence submitted needs to meet the stringent standards of regulators. ▪️ Integration into clinical workflow: To be useful, the system must slot seamlessly into existing PACS, reporting systems, and radiologist workflows without disruption. ▪️ Trust & transparency: Publishing scientific evidence, open methods, and validation results help institutions trust the system beyond just regulatory clearance. That’s the philosophy behind icometrix’s #icobrain platform. CE-marked, FDA-cleared, backed by extensive peer-reviewed research, and built to integrate smoothly into radiology workflows, #icobrain supports faster, more confident, clinically actionable decisions. As Dr. Dr Hugh Harvey emphasizes, the true benchmark is “diagnostic trust.” Very few #AI tools achieve it. icobrain already has. Hardian Health advises healthcare tech innovators on clinical strategy, regulatory clearance, health economics, IP, and more.